Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04480710 · ClinicalTrials.gov registry record · Phase 2
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
A Phase 2 study, sponsored by Hepion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT04480710 is a Phase 2 study that has completed, run by Hepion Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT04480710, a Phase 2 study, has completed, sponsored by Hepion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.
Interventions
- DRUG CRV431 75mg
- DRUG Placebo (1 softgel)
- DRUG CRV431 225mg
- DRUG Placebo (3 softgels)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-06-23 |
| Est. Completion | 2021-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04480710
The ClinicalTrials.gov registry entry for NCT04480710 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hepion Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CRV431 75mg is the first listed.
NCT04480710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04480710 about?
NCT04480710 is a clinical study titled "A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects". This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.
What is the current status of trial NCT04480710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2020-06-23. Estimated completion is 2021-10-30.
What interventions are being tested in trial NCT04480710?
The interventions under investigation include: CRV431 75mg (DRUG), Placebo (1 softgel) (DRUG), CRV431 225mg (DRUG), Placebo (3 softgels) (DRUG).
Who is sponsoring clinical trial NCT04480710?
This trial is sponsored by Hepion Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.